A laboratory can prove that an idea works. It cannot negotiate a patent license, close a financing round, recruit a board or decide where a company should live. Those jobs occupy the stretch between an invention and an institution. Michael Farmer built his career in that stretch.
His public biography reads like a tour of complicated systems. He began as an engineer in classified Department of Defense and intelligence assignments, working with Navy engineering, communications and computer systems. The postings took him through Hawaii, the South Pacific and Southeast Asia. Along the way came nuclear-power training, Navy diving training and a pilot license. The details feel almost cinematic, but their practical lesson is quieter: technical work happens inside organizations with strict constraints, specialized languages and expensive consequences.
Farmer later moved into management consulting at Harbridge House, the Boston firm formed by Harvard Business School professors. He led national healthcare and defense practices there over a decade. The subject matter changed, but the work still required translation. Engineers, executives, customers and institutions could agree on a goal while seeing entirely different paths to it. An operator had to make those paths converge.
A company is also an engineered system
Before biotechnology became the center of his résumé, Farmer accumulated operating roles across communications, consulting and technology. He was chief operating officer of the Hospital Satellite Network during its startup years. He co-founded Age Wave, a consultancy focused on the economic and social implications of an aging population. At the Houston-based Infotronics, where he served as president and CEO, he also held the COO role at parent company American Medical Communications. A published professional biography credits him with bringing those businesses to profitability after years of losses.
He later became managing partner of the WindRiver Group, advising large companies and growing startups, and chief operating officer of Veridian, a defense contractor whose work included cybersecurity for sensitive government networks. On the surface, a media company, a consulting practice and a defense contractor share little. Operationally, each asks the same questions. Where does information get stuck? Which risk belongs to whom? What can the organization afford to learn next?
That pattern became especially visible at HandyLab, an Ann Arbor startup built around University of Michigan research. The underlying work came from chemical engineering doctoral students Kalyan Handique and Sundaresh Brahmasandra and their faculty advisers, Mark Burns and David Burke. Their portable analysis technology had been recognized by Science in 1998. HandyLab launched in 2000, with Farmer serving as president and CEO during its early financing period.
In 2001, the company went looking for $3.5 million and raised $5.5 million. Farmer called the oversubscription an achievement, especially in that economy. Then he turned attention away from the celebratory number. The university’s technology-transfer team, he said, had been “absolutely crucial” to the startup, particularly in patent protection and business planning. “Without their contributions,” he added, “there wouldn’t be a HandyLab today.”
Tech Transfer was absolutely crucial to the start of the company.Michael Farmer on HandyLab
It is a useful window into his operating style without inventing a personality for him. Farmer did not describe the company as the product of one founder’s insight. He named the scaffolding. Researchers produced the invention. The university helped protect and package it. Investors and government contracts supplied time. Management assembled those contributions into a company capable of continuing the work.
Terms determine which experiments happen
By 2004, Farmer was chief operating officer at Prosetta, then a seven-person San Francisco biotechnology company. The company wanted to pursue work involving hepatitis C, but Chiron controlled a large patent estate around the virus and its genome. The customary license came with upfront and annual payments that a company of Prosetta’s size could not carry.
Farmer’s public explanation was blunt: “We concluded that if we had to pay those kinds of sums we were not going to go after hepatitis C.” The statement is interesting because it makes no attempt to dress a constraint as inspiration. A promising program can die from the timing of a payment. In a small company, finance is not separate from research strategy. It decides which research can begin.
The agreement that followed changed the distribution of risk. Chiron removed upfront and annual fees; if Prosetta eventually produced a marketable drug, Chiron would receive a higher royalty. The deal did not make the technical challenge easier. It made the attempt possible. That distinction captures much of the operator’s contribution: not proving the scientific claim, but designing conditions in which a team has the chance to prove or disprove it.
A lower cost now and a larger payment after success can align a small company’s runway with a partner’s upside.
Patents, planning, grants and institutional partners are part of the product path, not paperwork around it.
Proximity to talent, customers and collaborators can outweigh a larger relocation incentive.
The scientist establishes what may be true. The operator builds an organization able to keep asking.
The boardroom view
Farmer’s next visible chapter ran in parallel. From 2004 through 2012, he chaired Akonni Biosystems, a molecular-diagnostics company in Frederick, Maryland. At the 2007 opening of Akonni’s headquarters and laboratories, he described a microarray platform designed to work with common sample types. The technology packed many tiny test sites onto a card intended for use with a portable reader.
The location decision offers another small case study in operating judgment. Farmer said five states made offers to lure Akonni. The company stayed in Frederick because it sat near biotechnology peers and customers in both commercial and federal markets. Incentives are visible and easy to compare. Networks are harder to price. Akonni chose the network.
As chairman, Farmer spoke about manufacturing cost and speed as readily as scientific capability. In an industry publication, he described Akonni’s microarray production method as “simple and straightforward,” emphasizing the company’s effort to reduce per-array cost. The quote returns to the same boundary visible at HandyLab and Prosetta. A technology becomes commercially meaningful when it can be produced, financed and placed where someone can use it.
Engineering assignments across defense, Navy communications and computer systems.
Leadership across Harbridge House, Hospital Satellite Network, Age Wave, Infotronics, WindRiver Group and Veridian.
President and CEO of HandyLab during early fundraising and university technology transfer.
Chairman of Akonni Biosystems while also entering Prosetta’s operating leadership.
President and co-CEO of Prosetta Biosciences before retiring from the role.
Thirteen years in San Francisco
Farmer ultimately spent 13 years as president and co-CEO of Prosetta Biosciences. The company was built around research into the way proteins assemble into temporary, functional complexes inside cells. Its premise was that small molecules could modulate those assemblies, giving researchers another route to discover therapeutics. Farmer was not presented as the inventor of the platform. His lane was the company around it.
That lane matters in a research business where time horizons are long and evidence arrives unevenly. The organization has to survive negative results, partnership negotiations and the gap between a compelling mechanism and a practical product. It needs enough discipline to stop work that fails and enough patience to continue work that has not yet answered the important question. The public record does not expose Farmer’s day-to-day decisions, but the length of his tenure shows how long he stayed with the institutional side of that project.
A later professional biography says Farmer retired after those 13 years. Prosetta’s current leadership page no longer lists him, while the company continues under founder Vishwanath Lingappa. That ending fits the broader shape of Farmer’s career. He repeatedly entered organizations at the stage where difficult technology needed operating form, then moved on without converting the enterprise into a personal brand.
The company is also a technology. It has interfaces, failure modes and a design life of its own.The through-line in Farmer's career
Founder stories often flatten the people around the invention into a single word: business. Farmer’s résumé shows how many distinct jobs hide inside it. Negotiating a license is different from raising a round. Choosing a headquarters is different from chairing a board. Turning university intellectual property into a startup is different from operating a research platform for more than a decade. Yet each job serves the same purpose. It converts technical possibility into a sequence of decisions an institution can execute.
The practical lesson is available to any technical founder. Draw the complete translation chain. Name the institutions that control each handoff. Price the time a deal buys or consumes. Put the company near the people it needs. Give credit to the scaffolding, because the scaffolding is part of the build.
Michael Farmer’s career did not follow one industry upward. It followed one problem across industries: how to organize people and capital around systems that few outsiders fully understand. The engineer in the early chapters never quite disappeared. The object being engineered simply grew from equipment and communications networks into the company itself.